Inflammation, Rheumatoid Arthritis
Conditions
Brief summary
This trial is conducted in Europe. The aim of the trial is to investigate the mechanism of action of NNC0109-0012 (anti-IL-20 mAb) through synovial biopsies in subjects with rheumatoid arthritis (RA) and an inadequate response to Methotrexate.
Interventions
DRUGNNC0109-0012
Solution for injection administered subcutaneously (s.c. - under the skin). 240 mg NNC0109-0012 will be administered weekly for 12 weeks
DRUGAdalimumab
Solution for injection administered subcutaneously (s.c. - under the skin). Administered every other week for 12 weeks; Each active treatment involves 1 (one) s.c. injection of adalimumab 40 mg/0,8 mL solution for injection for paediatric use (Humira®)
DRUGplacebo
Solution for injection administered subcutaneously (s.c. - under the skin). 1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks).
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male or female age at least 18 and below or equal to 75 years at the time of signing informed consent * A diagnosis of RA at least 6 months prior to screening visit, according to the American College of Rheumatology (EULAR/ACR 2010 criteria) or by standard criteria (ACR 1987) if diagnosis was made earlier than 2010 * Subjects with ACR global functional status of 1 to 3 * Active RA, characterised by: DAS28 (Disease Activity Score 28) (CRP (C-reactive protein)) above 4.5 and equal to or above 6 tender and equal to or above 6 swollen joints based on a 66/68 joint count * Active Synovitis in at least two joints of the wrist and metacarpophalangeal joints, as assessed by high frequency Power Doppler ultrasound scan at screening and randomisation
Exclusion criteria
* Subjects with arthritis due to other autoimmune diseases than RA * Body weight above 90.0 kg * History of or current inflammatory joint disease other than RA (e.g. gout, psoriatic or reactive arthritis, Lyme disease, juvenile idiopathic arthritis, excluding secondary Sjogren syndrome and hypothyroidism) * Any active or on-going bacterial infections within 4 weeks prior to screening visit, unless treated and resolved with appropriate therapy or any history of recurrent infections or conditions predisposing to chronic infections (e.g., bronchiectasis, chronic osteomyelitis) * Subjects with malignancy within the previous 5 years with the exception of adequately treated and cured basal or squamous cell carcinoma of the skin or cervical carcinoma in situ occurring more than 12 months prior to screening visit * Female who is pregnant, breast feeding, intends to become pregnant or is of childbearing potential, not willing to use two highly effective contraceptive methods (adequate highlyeffective contraceptive measures are defined as established use of oral, injected or implanted hormonal methods of contraception, sterilisation, intrauterine device or intrauterine system) one of which has to be a barrier method a barrier method of contraception (e.g. condom with spermicidal foam/gel/film/cream), for at least 16 weeks (approximately 5 half-lives) following the last dose of trial medication * Male subjects who are sexually active and not surgically sterilised, who or whose partner are unwilling to use two different forms of highly effective contraception, one of which has to be a barrier method a barrier method of contraception (e.g. condom with spermicidal foam/gel/film/cream) for the duration of the trial and for at least 16 weeks (approximately 5 half-lives) following the last dose of trial medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the total histopathological synovitis score | Week 0, week 12 |
Secondary
| Measure | Time frame |
|---|---|
| Change in dynamic contrast enhanced MRI (DCE-MRI) measures of initial rate of enhancement (IRE) | Week 0, week 12 |
| Change in dynamic contrast enhanced MRI (DCE-MRI) measures of maximal enhancement (ME) | Week 0, week 12 |
| Changes in RA-MRI scores (RAMRIS (Rheumatoid arthritis magnetic resonance imaging)) of synovitis | Week 0, week 12 |
| Changes in RA-MRI scores (RAMRIS) of oedema | Week 0, week 12 |
| Changes in RA-MRI scores (RAMRIS) of erosion | Week 0, week 12 |
| Change in high frequency ultrasound with Power Doppler measures of total synovitis | Week 0, week 12 |
| Change in high frequency ultrasound with Power Doppler measures of total tenosynovitis scores | Week 0, week 12 |
| Change in disease activity 28 - C-reactive protein (DAS28 (CRP) | Week 0, week 12 |
| Incidence of Adverse Events (AE) | Week 0, week 24 |
| Incidence of local intolerability at the injection site | Week 0, week 24 |
Outcome results
None listed